Al-Majed For Oud reports strong Q4 FY25 performance with profits reaching USD 11M
According to the company, strong demand fueled revenue gains, complemented by enhanced margins and disciplined expense controls.
SAUDI ARABIA – Al-Majed for Oud Company has posted exceptional Q4 2025 results, with net profits skyrocketing 181% year-over-year to SAR 42.3 million(USD 11.27 million).
Compared to Q3 2025, net profit grew 40.4% from SAR 30.11 million(USD 8.01 million).
This performance underscores robust sales growth and tight cost management in the perfumes sector.
Revenues climbed 7.8% to SAR 252.23 million(USD 67.1 million) from SAR 234.06 million(USD 62.3 million) in Q4 2024, while gross income rose 13.1% to SAR 162.28 million(USD 43.1 million).
Operating income surged 142.5% to SAR 45.43 million(USD 12.1 million), boosting earnings per share to SAR 1.69(USD 0.45) from SAR 0.60(USD 0.16).
Annual net income reached SAR 217.6 million(USD 57.8 million), up 38.6% from SAR 157 million(USD 41.8 million) in 2024, with revenues expanding 19.2% to SAR 1,103.5 million(USD 293.5 million).
Gross income increased 18.6% to SAR 723.3 million(USD 192.3 million), and operating income advanced 33.1% to SAR 237.5 million(USD 63.1 million), lifting EPS to SAR 8.70(USD 2.31).
Shareholders’ equity reached SAR 584.3 million (USD 155.4 million) by year-end, up from SAR 468.2 million(USD 124.5 million) previously.
The company highlighted operational efficiency and financial prudence as key to sustaining long-term shareholder value.
In addition, segments such as perfumes, oud, incense, oils, and gifts drove diversified growth.
Al-Majed For Oud offers a diverse portfolio of luxury fragrance products centred on Arabian perfumery traditions.
Their range includes oud-based perfumes, perfumed oils, and traditional incense such as bakhoor, as well as air fresheners and curated gift sets.
In other news, Al Majed for Oud has entered into an exclusive memorandum of understanding (MoU) to acquire 100% of Al Safa Pharmaceuticals and Medical Supplies Limited Liability Company, marking a strategic step toward diversifying beyond its core fragrance and oud business into pharmaceuticals and health‑care distribution.
The MoU grants Al Majed the sole and exclusive right to negotiate a full acquisition of Al Safa’s share capital from its owners, Othman Abdullah Othman Al‑Suwaih, Abdullah Othman Abdullah Al‑Suwaih, and Amr Othman Abdullah Al‑Suwaih, a six‑month period, with the possibility of extension by mutual written agreement.
Under the terms of the MoU, Al Majed is currently evaluating the transaction through due diligence activities covering Al Safa’s operations, financial position, and regulatory standing, while the company cautions that the financial impact of any eventual deal cannot yet be determined.
The arrangement remains non‑binding at this stage and expressly falls under Tadawul’s continuous‑disclosure rules, with no related‑party issues reported between Al Majed and the sellers.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
